Table I.
Characteristics of the studies included in the meta-analysis.
| LOAD | Control | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Included studies | Population | Results | Cases (% female) | Diagnostic criteria | Average age of onset | Average age | Case (% female) | Average age | Genotyping | References |
| Caucasian | ||||||||||
| Lambert et al, 2009 | Stage 1 (France) | Pos | 2,025 (66%) | C | 68.3±9.0 | 73.7±8.9 | 5,328 (61%) | 73.8±5.4 | Illumina infinium system | (6) |
| Stage 2 (Italy) | Pos | 1,520 (68%) | C | 73.8±8.8 | 76.6±8.7 | 1,291 (55%) | 72.3±8.9 | Illumina infinium system | ||
| Stage 2 (Spain) | Neg | 755 (57%) | C | 72.5±9.4 | 75.3±9.3 | 833 (62%) | 76.9±10.9 | Illumina infinium system | ||
| Stage 2 (Belgium) | Pos | 1,084 (66%) | C | 74.4±8.6 | 78.6±8.1 | 509 (58%) | 67.0±12.9 | Illumina infinium system | ||
| Stage 2 (Finland) | Pos | 619 (67%) | C | 71.4±7.5 | 71.4±7.5 | 664 (60%) | 69.2±6.0 | Illumina infinium system | ||
| Harold et al, 2009 | Stage 1 (USA) | Pos | 1,159 (58%) | M | 73.5 | 80.7 | 1,783 (56%) | 68.1 | Illumina infinium system | (7) |
| Stage 1 (UK, Ireland) | Pos | 2,227 (65%) | M | 72.9 | 79.7 | 5,241 (53%) | 51.2 | Illumina infinium system | ||
| Stage 1 (Germany) | Pos | 555 (64%) | C | 70.5 | 72.9 | 824 (51%) | 56.5 | Illumina infinium system | ||
| Giedraitis et al, 2009 | Sweden (ULSAM) | Neg | 86 (0%) | C | 80.2 | – | 404 (0%) | 81.8 | Illumina GoldenGate assay | (9) |
| Golenkina et al, 2010 | Russian | Neg | 534 (−) | C | – | – | 702 (−) | – | – | (10) |
| Jun et al, 2010 | USA (ADGC-C) | Pos | 5,935 (−) | M | – | – | 7,034 (−) | – | Illumina or affymetrix arrays | (17) |
| Seshadri et al, 2010 | Spain (ACE) | Pos | 1,140 (70%) | C | – | 78.8±7.9 | 1,209 (53%) | 49.9±9.2 | Illumina or affymetrix arrays | (24) |
| Carrasquillo et al, 2010 | USA | Pos | 1,829 (−) | M | – | – | 2,576 (−) | – | TaqMan SNP genotyping assays | (13) |
| Schjeide et al, 2011 | Germany | Neg | 214 | C | – | – | 211 (−) | – | OpenArray genotyping system | (23) |
| USA | Pos | 2,654 | M | – | – | 1,175 (−) | – | OpenArray genotyping system | ||
| Bettens et al, 2012 | Stage 1 (Belgium) | Pos | 1,057 (66%) | C | 74.9±8.9 | – | 873 (57.4%) | 65.1±14.9 | PCR | (12) |
| Stage 2 (France) | Neg | 1,465 (66%) | C | 69.5±8.2 | – | 717 (62.3%) | 74.0±8.0 | PCR | ||
| Stage 2 (Canada) | Neg | 323 (55%) | C | 75.3±9.7 | – | 250 (60.0%) | 73.0±10.2 | PCR | ||
| Kamboh et al, 2012 | USA | Neg | 1,348 (66%) | M | 72.6±6.4 | – | 1,359 (61%) | 74.7±6.5 | TaqMan SNP genotyping assays | (18) |
| Carrasquillo et al, 2014 | USA | Pos | 54 (76%) | N | – | – | 2,523 (56.7%) | – | TaqMan SNP genotyping assays | (14) |
| Asian | ||||||||||
| Yu et al, 2010 | China | Neg | 324 (56%) | C | – | 76.8±5.5 | 388 (54%) | 75.9±4.6 | MALDI-TOF mass spectrometry | (25) |
| Gu et al, 2011 | Indiana | Neg | 106 (56%) | C | – | 76.7±7.0 | 98 (55.1%) | 76.1±7.1 | PCR | (11) |
| Ohara et al, 2012 | Japan | Pos | 824 (77%) | C | – | 83.2±6.5 | 2,933 (56.0%) | 60.2±11.5 | Invader assay | (22) |
| Lin et al, 2012 | Taiwan | Pos | 268 (−) | C | – | – | 389 (−) | – | – | (19) |
| Chen et al, 2012 | Hong Kong | Neg | 462 (−) | C | – | – | 350 (−) | – | Sequenom platform | (15) |
| Ma et al, 2012 | China | Neg | 127 (58%) | C | – | 73.1±8.6 | 143 (55.2%) | 73.8±6.3 | PCR-RFLP | (20) |
| Miyashita et al, 2013 | Stage 1 (Japan) | Pos | 1,008 (72%) | C | 73.0±4.3 | – | 1,016 (57%) | 77.0±5.9 | Affymetrix GeneChip 6.0 microarrays | (21) |
| Stage 3 (Korean) | Pos | 339 (72%) | C | – | 73.7±9.5 | 1,129 (49%) | 71.0±4.9 | TaqMan assays | ||
| Lu et al, 2014 | Stage 2 (China) | Neg | 499 (55%) | C | – | 70.0±10.0 | 592 (59.3%) | 68.9±9.4 | PCR-RFLP | (26) |
| African descent | ||||||||||
| Jun et al, 2010 | USA (ADGC-AA) | Neg | 462 (−) | M | – | – | 449 (−) | – | Illumina 660Quad | (17) |
| Hispanics | ||||||||||
| Jun et al, 2010 | USA (ADGC-H) | Neg | 549 (−) | M | – | – | 544 (−) | – | Illumina HumanHap 650Y chip | (17) |
| Other/Mixed | ||||||||||
| Jun et al, 2010 | USA (ADGC-Wadi Ara) | Neg | 124 (−) | M | – | – | 142 (−) | – | Illumina 660Quad | (17) |
| Ferrari et al, 2012 | UK | Pos | 342 (59%) | C | 76.8±8.6 | – | 277 (64.6%) | 70.2±8.6 | TaqMan SNP genotyping assays | (16) |
Pos, positive: statistically significant; Neg, negative: non statistically significant; Alzheimer's disease diagnostic criteria: C, clinical criteria; N, neuropathological criteria; M, mixture of clinical and neuropathological criteria; -, no data obtained; PCR, polymerase chain reaction; SNP, single nucleotide polymorphism; RFLP, restriction fragment length polymorphism; MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; ADGC-C, the Alzheimer's Disease Genetics Consortium-Caucasian; ADGC-AA, the ADGC-African American; ADGC-H, ADGC-Hispanics; ADGC-Wadi Ara, ADGC-Wadi Arab.